News|Articles|March 18, 2010

FDA Transparency Initiative Moves to Phase Three

In the final phase of its transparency initiative, the US Food and Drug Administration seeks additional public comments about how it can increase its interactions with regulated industry.

In the final phase of its transparency initiative, the US Food and Drug Administration seeks additional public comments about how it can increase its interactions with regulated industry, according to a Mar. 12, 2010 announcement in Federal Register.

FDA launched the Transparency Task Force in June 2009 with a transparency blog and website, which constituted the first phase of the project. The second phase involved two public meetings held in June 2009 and November 2009 to garner feedback from industry and the general public. The overall goal is to develop recommendations for making the agency’s “activities and decisions more useful, understandable, and readily available, while appropriately protecting confidential information,” according to an agency press release on the subject. The agency is expected to issue draft proposals soon regarding how it will increase its transparency in the long term.

Before it issues draft proposals, the agency would like to hear additional comments from industry. FDA recommends that industry read or listen to a series of sessions that were held with industry representatives in January 2010. The audio files and transcripts are available at www.fda.gov/transparency and at www.regulations.gov.

FDA is particularly interested in recommendations about how it can:
·        Train and educate regulated industry about the FDA regulatory and guidance-development processes
·        Maintain open channels of communication with industry routinely and during crises
·        Provide useful and timely answers to industry questions about specific regulatory issues

Comments are due on Apr. 12, 2010 and can be submitted at www.regulations.gov.
 
See related PharmTech articles:

FDA Bares All (blog post)

Transparency and Safety (blog post)

FDA Enters the Blogosphere with New Transparency Task Force (blog post)


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.